Deepti R Nagarkar1, Julie A Poposki1, Bruce K Tan2, Michael R Comeau3, Anju T Peters1, Kathryn E Hulse1, Lydia A Suh1, James Norton1, Kathleen E Harris1, Leslie C Grammer1, Rakesh K Chandra2, David B Conley2, Robert C Kern2, Robert P Schleimer4, Atsushi Kato5. 1. Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill. 2. Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Ill. 3. Department of Inflammation Research, Amgen, Seattle, Wash. 4. Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill; Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Ill. 5. Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: a-kato@northwestern.edu.
Abstract
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with TH2-dominant inflammation. Thymic stromal lymphopoietin (TSLP) is a cytokine that triggers dendritic cell-mediated TH2 inflammatory responses and that enhances IL-1-dependent TH2 cytokine production in mast cells. Although increased TSLP mRNA levels have been found in nasal polyps (NPs), expression of TSLP protein and its function in patients with chronic rhinosinusitis (CRS) have not been fully explored. OBJECTIVES: The objective of this study was to investigate the role of TSLP in patients with CRS. METHODS: We investigated the presence and stability of TSLP protein in NPs using ELISA and Western blotting and investigated the function of TSLP in nasal tissue extracts with a bioassay based on activation of human mast cells. RESULTS: Although TSLP mRNA levels were significantly increased in NP tissue from patients with CRSwNP compared with uncinate tissue from patients with CRS or control subjects, TSLP protein was significantly decreased in NP tissue, as detected by using the commercial ELISA kit. We found that recombinant TSLP was time-dependently degraded by NP extracts, and this degradation was completely inhibited by a protease inhibitor cocktail, suggesting that TSLP is sensitive to tissue proteases. Interestingly, NP extract-treated TSLP had higher activity in mast cells, although the amount of full-length TSLP was reduced up to 85%. NP extracts significantly enhanced IL-1β-dependent IL-5 production in mast cells compared with uncinate tissue homogenates, and responses were significantly inhibited by anti-TSLP, suggesting that NPs contain biologically relevant levels of TSLP activity. CONCLUSION: TSLP and its metabolic products might play an important role in the inflammation seen in patients with CRSwNP.
BACKGROUND:Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with TH2-dominant inflammation. Thymic stromal lymphopoietin (TSLP) is a cytokine that triggers dendritic cell-mediated TH2 inflammatory responses and that enhances IL-1-dependent TH2 cytokine production in mast cells. Although increased TSLP mRNA levels have been found in nasal polyps (NPs), expression of TSLP protein and its function in patients with chronic rhinosinusitis (CRS) have not been fully explored. OBJECTIVES: The objective of this study was to investigate the role of TSLP in patients with CRS. METHODS: We investigated the presence and stability of TSLP protein in NPs using ELISA and Western blotting and investigated the function of TSLP in nasal tissue extracts with a bioassay based on activation of human mast cells. RESULTS: Although TSLP mRNA levels were significantly increased in NP tissue from patients with CRSwNP compared with uncinate tissue from patients with CRS or control subjects, TSLP protein was significantly decreased in NP tissue, as detected by using the commercial ELISA kit. We found that recombinant TSLP was time-dependently degraded by NP extracts, and this degradation was completely inhibited by a protease inhibitor cocktail, suggesting that TSLP is sensitive to tissue proteases. Interestingly, NP extract-treated TSLP had higher activity in mast cells, although the amount of full-length TSLP was reduced up to 85%. NP extracts significantly enhanced IL-1β-dependent IL-5 production in mast cells compared with uncinate tissue homogenates, and responses were significantly inhibited by anti-TSLP, suggesting that NPs contain biologically relevant levels of TSLP activity. CONCLUSION:TSLP and its metabolic products might play an important role in the inflammation seen in patients with CRSwNP.
Authors: Sarah Peterson; Julie A Poposki; Deepti R Nagarkar; Regina T Chustz; Anju T Peters; Lydia A Suh; Roderick Carter; James Norton; Kathleen E Harris; Leslie C Grammer; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato Journal: J Allergy Clin Immunol Date: 2011-09-23 Impact factor: 10.793
Authors: P A Reche; V Soumelis; D M Gorman; T Clifford; M Travis; S M Zurawski; J Johnston; Y J Liu; H Spits; R de Waal Malefyt; R A Kastelein; J F Bazan Journal: J Immunol Date: 2001-07-01 Impact factor: 5.422
Authors: Jenny M Mjösberg; Sara Trifari; Natasha K Crellin; Charlotte P Peters; Cornelis M van Drunen; Berber Piet; Wytske J Fokkens; Tom Cupedo; Hergen Spits Journal: Nat Immunol Date: 2011-09-11 Impact factor: 25.606
Authors: Aarti Shikotra; David F Choy; Chandra M Ohri; Emma Doran; Claire Butler; Beverley Hargadon; Maria Shelley; Alexander R Abbas; Cary D Austin; Janet Jackman; Lawren C Wu; Liam G Heaney; Joseph R Arron; Peter Bradding Journal: J Allergy Clin Immunol Date: 2011-10-05 Impact factor: 10.793
Authors: Sun Ying; Brian O'Connor; Jonathan Ratoff; Qiu Meng; Kirsty Mallett; David Cousins; Douglas Robinson; Guizhen Zhang; Jisheng Zhao; Tak H Lee; Chris Corrigan Journal: J Immunol Date: 2005-06-15 Impact factor: 5.422
Authors: C Bachert; N Van Bruaene; E Toskala; N Zhang; H Olze; G Scadding; C M Van Drunen; J Mullol; L Cardell; P Gevaert; T Van Zele; S Claeys; C Halldén; K Kostamo; U Foerster; M Kowalski; K Bieniek; A Olszewska-Ziaber; E Nizankowska-Mogilnicka; A Szczeklik; M Swierczynska; M Arcimowicz; V Lund; W Fokkens; T Zuberbier; C Akdis; G Canonica; P Van Cauwenberge; P Burney; J Bousquet Journal: Allergy Date: 2009-04 Impact factor: 13.146
Authors: Bruce K Tan; Aiko I Klingler; Julie A Poposki; Whitney W Stevens; Anju T Peters; Lydia A Suh; James Norton; Roderick G Carter; Kathryn E Hulse; Kathleen E Harris; Leslie C Grammer; Robert P Schleimer; Kevin C Welch; Stephanie S Smith; David B Conley; Robert C Kern; Atsushi Kato Journal: J Allergy Clin Immunol Date: 2016-09-14 Impact factor: 10.793
Authors: Whitney W Stevens; Christopher J Ocampo; Sergejs Berdnikovs; Masafumi Sakashita; Mahboobeh Mahdavinia; Lydia Suh; Tetsuji Takabayashi; James E Norton; Kathryn E Hulse; David B Conley; Rakesh K Chandra; Bruce K Tan; Anju T Peters; Leslie C Grammer; Atsushi Kato; Kathleen E Harris; Roderick G Carter; Shigeharu Fujieda; Robert C Kern; Robert P Schleimer Journal: Am J Respir Crit Care Med Date: 2015-09-15 Impact factor: 21.405
Authors: Mahboobeh Mahdavinia; Roderick G Carter; Christopher J Ocampo; Whitney Stevens; Atsushi Kato; Bruce K Tan; Robert C Kern; David B Conley; Rakesh Chandra; Kathryn E Hulse; Lydia A Suh; James E Norton; Anju T Peters; Leslie C Grammer; Lawrence B Schwartz; Robert P Schleimer Journal: J Allergy Clin Immunol Date: 2014-03-15 Impact factor: 10.793